Cost-effectiveness of activated protein C in real-life clinical practice

BACKGROUND: Recombinant human activated protein C (rhAPC) has been reported to be cost-effective in severely ill septic patients in studies using data from a pivotal randomized trial. We evaluated the cost-effectiveness of rhAPC in patients with severe sepsis and multiple organ failure in real-life...

Descripción completa

Detalles Bibliográficos
Autores principales: Dhainaut, Jean-François, Payet, Stéphanie, Vallet, Benoit, França, Lionel Riou, Annane, Djillali, Bollaert, Pierre-Edouard, Tulzo, Yves Le, Runge, Isabelle, Malledant, Yannick, Guidet, Bertrand, Le Lay, Katell, Launois, Robert
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2007
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2556742/
https://www.ncbi.nlm.nih.gov/pubmed/17822547
http://dx.doi.org/10.1186/cc6116

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2556742/
https://www.ncbi.nlm.nih.gov/pubmed/17822547
http://dx.doi.org/10.1186/cc6116

Ejemplares similares